Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,918,995

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Tracey Ryniec headshot

The Story of the Greatest Mom and Pop Investor Ever

Anne Scheiber grew $5,000 into $22 million over 50 years. How'd she do it?

Merck (MRK) Enters Into Circular RNA Collaboration With Orna

Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.

Quest Diagnostics' (DGX) Base Volume Revives, New Ruling Aids

With a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.

Here's Why You Should Retain Thermo Fisher (TMO) Stock Now

Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.

AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag

FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.

Is Invesco Dow Jones Industrial Average Dividend ETF (DJD) a Strong ETF Right Now?

Smart Beta ETF report for DJD

Illumina (ILMN) Q2 Earnings Miss Estimates, Slashes '22 View

Robust sales contribution across operating segments drove Illumina's (ILMN) Q2 top line.

Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

bluebird bio (BLUE) Focused on Pipeline Amid Marketed Drug Dearth

bluebird bio's (BLUE) efforts to develop its gene-therapy pipeline are impressive. The FDA is reviewing BLUE's filing for beti-cel as a treatment for beta thalassemia and eli-cel for cerebral adrenoleukodystrophy.

National Vision (EYE) Q2 Earnings Top Mark, Revenue View Cut

National Vision (EYE) is simultaneously facing demand headwinds across its network of stores, given the current macro environment, as well as supply challenges.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up

ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.

J&J (JNJ) to Stop Selling Talc-based Baby Powder From 2023

J&J (JNJ) will stop selling its talcum-based baby powder globally from next year. Though reports claim that the use of the talc causes cancer, JNJ maintains its stance that this product is safe.

STERIS (STE) Gains From Cantel Buyout, Supply Chain Issue Stays

Revenue growth at STERIS' (STE) Applied Sterilization Technologies is driven by increased demand from medical device and biopharma customers.

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up

Haemonetics (HAE) posts better-than-expected results in Q1 with robust contributions from the Hospital business.

Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe

Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.

Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down

Robust sales contribution from product and services segments drove Omnicell's (OMCL) Q2 top line.

Exelixis (EXEL) Q2 Earnings Beat, Cabometyx Maintains Growth

Exelixis (EXEL) tops earnings and sales in the second quarter as lead drug Cabometyx maintains momentum.

SmileDirectClub (SDC) Q2 Earnings Lag Estimates, Guidance Cut

SmileDirectClub (SDC) witnesses a drop in both net and financing revenues on a year-over-year basis.

Sheraz Mian headshot

Q2 Earnings Scorecard and Analyst Reports for Roche, Adobe & McDonald's

Today's Research Daily features update on the Q2 earnings season and new research reports on Roche (RHHBY), Adobe (ADBE), and McDonald's (MCD).

Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up

Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Santanu Roy  headshot

The Zacks Analyst Blog Highlights Exxon Mobil, Merck & Co, Chevron, American Electric Power and The Southern

Exxon Mobil, Merck & Co, Chevron, American Electric Power and The Southern are part of Zacks Analyst Blog.

NuVasive (NUVA) Q2 Earnings Miss Estimates, Revenues Beat

NuVasive's (NUVA) Q2 revenues outpaced the consensus mark with strong sales across U.S. Spinal Hardware and Surgical Support businesses.

Nalak Das headshot

5 High-Flying U.S. Corporate Giants to Buy Despite Volatility

We have narrowed our search to five U.S. corporate giants. These are; XOM, CVX, AEP, MRK and SO.